Senti Biosciences

Senti Biosciences ROA

The Return on Assets (ROA) of Senti Biosciences (SNTI) as of Oct 24, 2026 is -119.94 %. In the previous year, Return on Assets (ROA) was -53.95 % — a change of 122.30% (lower).

ROA

-119.94 %

YoY

122.30%

Last updated:

In 2025, Senti Biosciences's return on assets (ROA) was -119.94 %, a 122.30% increase from the -53.95 % ROA in the previous year.

The Senti Biosciences ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-59.03 USD
Jan 1, 2020
-41.08 USD
Jan 1, 2021
-57.21 USD
Jan 1, 2022
-25.33 USD
Jan 1, 2023
-59.47 USD
Jan 1, 2024
-53.95 USD
Jan 1, 2025
-119.94 USD
The Senti Biosciences ROA history
YEARROAYoY
-119.94 %+122.30%
-53.95 %-9.27%
-59.47 %+134.80%
-25.33 %-55.72%
-57.21 %+39.24%
-41.08 %-30.40%
-59.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Senti Biosciences Stock analysis

What does Senti Biosciences do? Senti Biosciences develops cell and gene therapies using its gene circuit platform, targeting diseases like cancer. The company's products SENTI-202, SENTI-401, and SENTI-301A are designed for specific treatments: SENTI-202 is an off-the-shelf CAR-NK therapy targeting cancer while sparing bone marrow, SENTI-401 addresses colorectal cancer and solid tumors, and SENTI-301A targets hepatocellular carcinoma and other solid tumors. The gene circuit platform is modality-agnostic, applicable to NK cells, T cells, TILs, stem cells, and in vivo gene therapies like AAV and mRNA. The firm generates revenue through the development and potential commercialization of its therapeutic candidates. SENTI-202, SENTI-401, and SENTI-301A are in development stages, with SENTI-202 focusing on Logic Gated (OR + NOT) CAR-NK cell therapy. The company targets oncology segments, particularly for cancer treatments requiring precise targeting mechanisms. Its platform technology enables flexible application across various cell types and therapeutic modalities. Senti Biosciences' business model relies on advancing its pipeline candidates toward clinical trials and eventual market entry. The company's focus on engineered therapies using gene circuits positions it within the biotechnology sector, targeting specific disease areas with innovative approaches. The development of these therapies is intended to address unmet medical needs in oncology. Senti Biosciences is one of the most popular companies on Eulerpool.

ROA Details

Understanding Senti Biosciences's Return on Assets (ROA)

Senti Biosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Senti Biosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Senti Biosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Senti Biosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Senti Biosciences stock

Return on Assets (ROA) of Senti Biosciences is -119.94 % in 2025.

Return on Assets (ROA) of Senti Biosciences changed from -53.95 % to -119.94 %, representing a 122.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Senti Biosciences since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Senti Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Senti Biosciences

All Key Metrics — Senti Biosciences